Disease Report: Sepsis

1. Disease Summary

• WHO Sepsis Fact Sheet
• WSC Spotlight: Unmet Need in Sepsis Diagnosis and Therapy

2. Global Prevalence and Disease Burden

• Incidence: ~48.9 million cases annually worldwide (2017 estimate).
• Mortality: ~11 million deaths per year, accounting for 19.7% of all global deaths.
• Economic Impact: In the UK alone, the annual economic burden is estimated at £7.42 billion (direct and indirect costs). In the US, sepsis is the most expensive condition treated in hospitals, costing over $24 billion annually.
• Long-term Impact: Many survivors suffer from long-term physical, psychological, and cognitive sequelae, increasing the burden on healthcare systems and families.

• Sepsis in 2024: a review - ScienceDirect
• WHO Guidelines on the Clinical Management of Sepsis (2024)

3. Unmet Medical Need

A. Early and Accurate Diagnosis

• Current Limitation: Sepsis diagnosis is often delayed due to non-specific symptoms and lack of rapid, reliable diagnostic tools. Existing clinical criteria (e.g., SOFA, qSOFA) have limited sensitivity and specificity, especially in early or atypical presentations.
• Unmet Need: Rapid, sensitive, and specific diagnostic tests (including point-of-care and molecular diagnostics) and validated biomarkers to distinguish sepsis from other inflammatory conditions and to identify causative pathogens quickly.
• Contrast: Current reliance on clinical judgment and slow laboratory cultures leads to delayed or inappropriate therapy, increasing mortality.
• Sources:
  • WSC Spotlight: Unmet Need in Sepsis Diagnosis and Therapy
  • SelectScience summary of WSC 2024

B. Risk Stratification and Prognosis

• Current Limitation: Lack of tools to accurately predict which patients will deteriorate or benefit from specific interventions.
• Unmet Need: Predictive modeling (including AI and machine learning) to stratify risk, guide resource allocation, and personalize care.
• Contrast: Current scoring systems are imperfect and not universally adopted.
• Sources:
  • WSC Spotlight: Unmet Need in Sepsis Diagnosis and Therapy

C. Therapeutic Gaps

• Current Limitation: No targeted therapies exist for sepsis beyond supportive care (antibiotics, fluids, vasopressors). Immunomodulatory and adjunctive therapies have not consistently improved outcomes in trials.
• Unmet Need: Novel therapies targeting the underlying pathophysiology (e.g., immune modulation, endothelial protection, anti-inflammatory agents), and rapid-acting antimicrobials effective against resistant organisms.
• Contrast: Current treatments are non-specific and often initiated late due to diagnostic delays.
• Sources:
  • Sepsis in 2024: a review - ScienceDirect
  • WSC Spotlight: Unmet Need in Sepsis Diagnosis and Therapy

D. Antimicrobial Resistance (AMR)

• Current Limitation: Rising AMR complicates empiric therapy and increases mortality.
• Unmet Need: Rapid diagnostics for resistance profiling, new antimicrobials, and stewardship strategies tailored to sepsis.
• Contrast: Empiric broad-spectrum antibiotics are standard but may be ineffective or promote resistance.
• Sources:
  • WSC Spotlight: Unmet Need in Sepsis Diagnosis and Therapy

E. Personalized and Precision Medicine

• Current Limitation: Sepsis is heterogeneous; one-size-fits-all approaches are suboptimal.
• Unmet Need: Biomarker-driven and phenotype-based treatment strategies to tailor interventions to individual patient profiles.
• Contrast: Current protocols do not account for patient-specific immune responses or comorbidities.
• Sources:
  • WSC Spotlight: Unmet Need in Sepsis Diagnosis and Therapy

F. Management in Special Populations

• Current Limitation: Pediatric, neonatal, surgical, and immunocompromised patients have unique risks and presentations.
• Unmet Need: Age- and context-specific diagnostic and therapeutic guidelines, including for resource-limited settings.
• Contrast: Most guidelines are adult-centric and not adapted for all populations.
• Sources:
  • WSC Spotlight: Unmet Need in Sepsis Diagnosis and Therapy

G. Post-Discharge and Long-Term Care

• Current Limitation: Survivors often experience long-term sequelae (physical, cognitive, psychological) with little structured follow-up.
• Unmet Need: Comprehensive post-sepsis care pathways, rehabilitation, and support services.
• Contrast: Current care often ends at hospital discharge.
• Sources:
  • WSC Spotlight: Unmet Need in Sepsis Diagnosis and Therapy

H. Resource-Limited Settings

• Current Limitation: Lack of access to diagnostics, therapeutics, and critical care infrastructure.
• Unmet Need: Affordable, scalable solutions for early recognition and management in low- and middle-income countries.
• Contrast: Disparities in outcomes are stark between high- and low-resource settings.
• Sources:
  • WHO Guidelines on the Clinical Management of Sepsis (2024)

I. Awareness, Education, and Systemic Barriers

• Current Limitation: Low public and healthcare provider awareness leads to delayed recognition and treatment.
• Unmet Need: Global education campaigns, standardized training, and system-wide protocols.
• Contrast: Many cases are missed or treated late due to lack of awareness.
• Sources:
  • WHO Director-General: "Nobody Should Die from Sepsis"

4. Current Treatment Options

• Antibiotics: Empiric broad-spectrum antibiotics, adjusted based on culture results.
• Fluid Resuscitation: Intravenous fluids to restore perfusion; however, optimal type and volume remain debated (hypervolemia can worsen outcomes).
• Vasopressors: For patients with septic shock to maintain blood pressure.
• Supportive Care: Oxygen, mechanical ventilation, renal replacement therapy as needed.
• Source Control: Surgical or procedural intervention to eliminate the source of infection.
• Limitations: These interventions are non-specific, often delayed, and do not address the underlying immune dysregulation. No targeted therapies have consistently improved survival in large trials.

• Sepsis in 2024: a review - ScienceDirect
• WHO Guidelines on the Clinical Management of Sepsis (2024)

5. Current Clinical Trials

• Diagnostics: Trials of rapid molecular diagnostics, point-of-care tests, and novel biomarkers (e.g., procalcitonin, presepsin, host gene expression signatures).
• Therapeutics: Investigational immunomodulators, anti-inflammatory agents, endothelial protectants, and new antibiotics.
• AI and Predictive Modeling: Studies evaluating machine learning algorithms for early detection and risk stratification.
• Personalized Medicine: Trials stratifying patients by immune phenotype or biomarker profile to guide therapy.

• WSC Spotlight: Unmet Need in Sepsis Diagnosis and Therapy
• ClinicalTrials.gov

6. Additional Context

• Global Health Priority: The WHO and Global Sepsis Alliance have declared sepsis a global health priority, emphasizing the need for innovation, education, and system-wide change.
• Disparities: Outcomes are worse in low- and middle-income countries due to limited resources.
• COVID-19 Impact: The pandemic has highlighted the importance of rapid sepsis recognition and management, as severe COVID-19 often presents as viral sepsis.
• Economic Burden: The high cost of sepsis care and long-term disability underscores the need for more effective prevention, diagnosis, and treatment strategies.

• WHO Guidelines on the Clinical Management of Sepsis (2024)
• WSC Spotlight: Unmet Need in Sepsis Diagnosis and Therapy

Summary Table: Unmet Medical Needs in Sepsis

References

• WSC Spotlight: Unmet Need in Sepsis Diagnosis and Therapy
• WHO Guidelines on the Clinical Management of Sepsis (2024)
• Sepsis in 2024: a review - ScienceDirect
• SelectScience summary of WSC 2024
• ClinicalTrials.gov - Sepsis